These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 30171535)

  • 21. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy.
    Osman EY; Yen PF; Lorson CL
    Mol Ther; 2012 Jan; 20(1):119-26. PubMed ID: 22031236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
    Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
    Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
    Nakevska Z; Yokota T
    Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spinal muscular atrophy.
    Arnold ES; Fischbeck KH
    Handb Clin Neurol; 2018; 148():591-601. PubMed ID: 29478602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic approaches for spinal muscular atrophy (SMA).
    Scoto M; Finkel RS; Mercuri E; Muntoni F
    Gene Ther; 2017 Sep; 24(9):514-519. PubMed ID: 28561813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.
    Singh NN; Luo D; Singh RN
    Methods Mol Biol; 2018; 1828():415-437. PubMed ID: 30171557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
    Li Y; Zeng H; Wei Y; Ma X; He Z
    Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
    Leckie J; Yokota T
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-Based Therapy for Spinal Muscular Atrophy.
    Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y
    Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
    Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
    Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
    Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene.
    Pao PW; Wee KB; Yee WC; Pramono ZA
    Mol Ther; 2014 Apr; 22(4):854-61. PubMed ID: 24317636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes.
    Singh NN; Seo J; Rahn SJ; Singh RN
    PLoS One; 2012; 7(11):e49595. PubMed ID: 23185376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
    Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
    Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.